Harrow earnings release, May 11, 2026

Harrow, Inc. (HROW) · Form 8-K, Item 2.02 · Filed · SEC filing

Harrow

Announces First Quarter 2026 Financial Results

First

Quarter 2026 and Selected Highlights:

NASHVILLE,

Tenn., May 11, 2026 – Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the first quarter ended March 31, 2026. The Company also posted its first-quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website at harrow.com. The Company encourages Harrow stockholders to review these documents, which provide additional details concerning the historical results and future expectations for the business.

“The demand for Harrow’s key products has never been stronger, and our visibility into our demand trajectory – across our portfolio – keeps us entirely on track to reach our forecasted financial goals for the year,” said Mark

L. Baum, Chief Executive Officer of Harrow. “Although our first-quarter reported revenue reflects an estimated $8 million gross-to-net reduction associated with our new commercial coverage for VEVYE, this adjustment does not reflect the profitable, recurring, and significant patient base established during the quarter. Harrow is now positioned to realize the full financial benefits of this coverage relationship beginning in Q2 2026.”

Baum continued, “Prior to the quarter, we established business rules with specific assumptions regarding these new

VEVYE commercial patients. As the period unfolded, the surge in demand among patients with high-deductible plans significantly outpaced our initial models. This created temporary gross-to-net pressure, which was resolved through business rules adjustments. With these rules now in place, we are now positioned to realize the expected financial benefit of our expanded commercial access, and we are already seeing highly encouraging net pricing indicators early in the second quarter.”

“Our core commercial engine is accelerating. VEVYE delivered record prescription performance and has officially surpassed XIIDRA on a monthly total prescription basis. Across our key growth drivers - VEVYE, IHEEZO, and TRIESENCE - we are seeing robust prescriber adoption, expanding market share, and durable momentum. With our expanded commercial organization now fully deployed, we remain highly confident in our ability to deliver on our 2026 revenue guidance of $350 million to $365 million.”

Key

First Quarter Demand Indicators

:

VEVYE:

IHEEZO:

TRIESENCE:

First

Quarter 2026 Financial Results:

Conference

Call and Webcast

Harrow will host a conference call to discuss the results at 8:00 a.m. ET on Tuesday, May 12, 2026. Participants can access the live webcast of Harrow’s presentation on the “Investors” page of Harrow’s website. A replay of the webcast will be available on the Company’s website for one year.

To participate via telephone, please register in advance using this link. Upon registration, all telephone participants will receive a confirmation email with detailed instructions, including a unique dial-in number and PIN, to access the call.

About

Harrow

Harrow,

Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma, and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on

LinkedIn.

Forward-Looking

Statements

Financial statements

Income Statement

For the Three Months Ended March 31, — Additional product-related revenue figures are reflected in the table below:

For the Three Months Ended March 31, – 2026For the Three Months Ended March 31, – 2026For the Three Months Ended March 31, – 2025For the Three Months Ended March 31, – 2025
IHEEZO1,851,0004.0%5,222,00011.0%
VEVYE20,947,00047.0%21,516,00045.0%
Other branded products7,833,00018.0%956,0002.0%
Other revenues73,0000.0%86,0000.0%
Branded revenue, net30,704,00069.0%27,780,00058.0%
ImprimisRx revenue, net13,499,00031.0%20,051,00042.0%
Total revenues, net44,203,000100.0%47,831,000100.0%

Income Statement

For the Three Months Ended March 31, — Selected financial highlights regarding GAAP operating results for the three months ended March 31, 2026 and 2025 are as follows:

For the Three Months Ended March 31, – 2026For the Three Months Ended March 31, – 2025
Total revenues44,203,00047,831,000
Cost of sales-17,158,000-15,524,000
Gross profit27,045,00032,307,000
Selling, general and administrative43,230,00040,513,000
Research and development5,895,0003,026,000
Total operating expenses49,125,00043,539,000
Loss from operations-22,080,000-11,232,000
Interest expense, net-5,497,000-6,548,000
Income tax expense-25,000
Net loss-27,602,000-17,780,000
Net loss per share:Basic-0.74-0.5
Net loss per share:Diluted-0.74-0.5

Income Statement

For the Three Months Ended March 31, — Selected financial highlights regarding Non-GAAP operating results for the three months March 31, 2026 and 2025 are as follows:

For the Three Months Ended March 31, – 2026For the Three Months Ended March 31, – 2025
Total revenues44,203,00047,831,000
Gross margin61.0%68.0%
Net loss-27,602,000-17,780,000
Adjusted EBITDA(1)-12,659,000-1,985,000
Net loss per share:Basic-0.74-0.5
Net loss per share:Diluted-0.74-0.5

Income Statement

For the Three Months Ended March 31,

For the Three Months Ended March 31, – 2026For the Three Months Ended March 31, – 2025
GAAP net loss-27,602,000-17,780,000
Stock-based compensation and expenses3,837,0004,556,000
Interest expense, net5,497,0006,548,000
Income tax expense25,000
Depreciation455,000465,000
Amortization of intangible assets5,129,0004,226,000
Adjusted EBITDA-12,659,000-1,985,000

Income Statement

For the Three Months Ended March 31, — First Quarter 2026 Financial Results:

For the Three Months Ended March 31, – 2026For the Three Months Ended March 31, – 2025
Total revenues44,203,00047,831,000
Gross margin61.0%68.0%
Net loss-27,602,000-17,780,000
Adjusted EBITDA(1)-12,659,000-1,985,000
Net loss per share, basic and diluted-0.74-0.5

Income Statement

For the Three Months Ended March 31, — UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

For the Three Months Ended March 31, – 2026For the Three Months Ended March 31, – 2025
Total revenues44,203,00047,831,000
Cost of sales-17,158,000-15,524,000
Gross profit27,045,00032,307,000
Selling, general and administrative43,230,00040,513,000
Research and development5,895,0003,026,000
Total operating expenses49,125,00043,539,000
Loss from operations-22,080,000-11,232,000
Interest expense, net-5,497,000-6,548,000
Income tax expense-25,000
Net loss-27,602,000-17,780,000
Net loss per share:Basic and diluted-0.74-0.5

Income Statement

For the Three Months Ended March 31, — RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA

For the Three Months Ended March 31, – 2026For the Three Months Ended March 31, – 2025
GAAP net loss-27,602,000-17,780,000
Stock-based compensation and expenses3,837,0004,556,000
Interest expense, net5,497,0006,548,000
Income tax expense25,000
Depreciation455,000465,000
Amortization of intangible assets5,129,0004,226,000
Adjusted EBITDA-12,659,000-1,985,000

Balance Sheet

March 31, 2026 — CONDENSED CONSOLIDATED BALANCE SHEETS

March 31, 2026December 31, 2025
ASSETSCash and cash equivalents94,644,00072,927,000
ASSETSAll other current assets131,740,000138,823,000
ASSETSTotal current assets226,384,000211,750,000
ASSETSAll other assets193,159,000187,732,000
ASSETSTOTAL ASSETS419,543,000399,482,000
LIABILITIES AND STOCKHOLDERS’ EQUITYCurrent liabilities91,439,00096,302,000
LIABILITIES AND STOCKHOLDERS’ EQUITYLoans payable, net of unamortized debt discount292,087,000243,184,000
LIABILITIES AND STOCKHOLDERS’ EQUITYAll other liabilities7,666,0007,905,000
LIABILITIES AND STOCKHOLDERS’ EQUITYTOTAL LIABILITIES391,192,000347,391,000
LIABILITIES AND STOCKHOLDERS’ EQUITYTOTAL STOCKHOLDERS’ EQUITY28,351,00052,091,000
LIABILITIES AND STOCKHOLDERS’ EQUITYTOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY419,543,000399,482,000

Cash Flow

For the Three Months Ended March 31, — CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Three Months Ended March 31, – 2026For the Three Months Ended March 31, – 2025
Net cash provided by (used in):Operating activities-8,992,00019,668,000
Net cash provided by (used in):Investing activities-18,203,000-212,000
Net cash provided by (used in):Financing activities48,912,00023,000
Net cash provided by (used in):Net change in cash and cash equivalents21,717,00019,479,000
Net cash provided by (used in):Cash and cash equivalents at beginning of the period72,927,00047,247,000
Net cash provided by (used in):Cash and cash equivalents at end of the period94,644,00066,726,000
Full release

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward—looking statements.”

Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general, including the ongoing communications with the U.S. Food and Drug Administration relating to compliance and quality plans at our outsourcing facility in New Jersey; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow’s filings with the Securities and Exchange

Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025, and other filings with the SEC. Such... (truncated)of charge on the SEC’s web site at sec.gov. Undue reliance should not be placed on forward-looking-statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking-statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Contact:

Mike

Biega, VP of Investor Relations and Communications mbiega@harrowinc.com

617-913-8890

HARROW, INC.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Harrow earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.